Liver function tests during treatment with antipsychotic drugs: A case series of 23 patients

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 26, Issue 7-8, 2002, Pages 1409-1411

  Mouradian Stamatiadis, Laurence ^a   Dumortier, Gilles ^a   Januel, Dominique ^a   Delmas, Beatrice Aubriot ^a   Cabaret, Wanda ^a  

^a Service du Docteur Glikman   (France)

Author keywords

Antipsychotics; Hepatitis; Iatrogenicity

Indexed keywords

AMISULPRIDE; CLOZAPINE; LIVER ENZYME; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS; HUMAN; LIVER FUNCTION TEST; MALE; RISK FACTOR; SCHIZOPHRENIA;

ADOLESCENT; ADULT; AGED; FEMALE; HEPATITIS, TOXIC; HUMANS; LIVER; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SCHIZOPHRENIA;

EID: 0036890391     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(02)00263-4     Document Type: Article

References (18)

1. Biour M., Poupon R., Grange J.D., Chazouilleres O., Levy V.G., Bodin F., Cheymol G. Hepatotoxicity of drugs. 9th update of the bibliographic database of hepatic involvements and related drugs. Gastroenterol. Clin. Biol. 20(10):1996;744-779.
2. Cadario B.O. Olanzapine (Zyprexa*): suspected serious reactions. CMAJ, Can. Med. Assoc. J. 163(1):2000;85-86.
3. Conley R.R., Mahmoud R. A randomised double-blind study of risperidone and olanzapine in the treatment of schizoaffective disorder. Am. J. Psychiatr. 158:2001;765-774.
4. Cuffel B.J., Heithoff K.A., Lawson W. Correlates of patterns of substance abuse among patients with schizophrenia. Hosp. Community Psychiatry. 44:1993;247-251.
5. Diagnostic and Statistic Manual Mental Disorder. 1996;Ed Masson, Paris.
6. Gaertner I., Altendorf K., Batra A., Gaertner H.J. Relevance of liver enzyme elevations with four different neuroleptics: a retrospective review of 7,263 treatment courses. J. Clin. Psychopharmacol. 21(2):2001;215-222.
7. Hummer M., Kurz M., Kurzthaler I., Oberbauer H., Miller C., Fleischhacker W.W. Hepatotoxicity of clopazine. J. Clin. Psychopharmacol. 17(4):1997;314-317.
8. Krebs S., Dormann H., Muth-Selbach U., Hahn E.G., Brune K., Schneider H.T. Risperidone-induced cholestatic hepatitis. Eur. J. Gastroenterol. Hepatol. 13(1):2001;67-69.
9. Larsen J.T., Clemensen S.V., Klitgaard N.A., Nielsen B., Brosen K. Clozapine-induced toxic hepatitis. Ugeskr. Læger. 163(14):2001;2013-2014.
10. Leppig M., Bosch B., Naber D., Hippius H. Clozapine in the treatment of 121 out patients. Psychopharmacology, Suppl. 99:1989;S77-S79.
11. Mayoral W., Lewis J.H. Drugs-induced liver disease. Curr. Opin. Gastroenterol. 16:2000;231-238.
12. Panagiotis B. Grand mal seizures with liver toxicity in a case of clozapine treatment. J. Neuropsychiatry Clin. Neurosci. 11(1):1999;117-118.
13. Raz A., Bergman R., Eilam O., Yungerman T., Hayek T. A case report of olanzapine-induced hypersensitivity syndrome. Am. J. Med. Sci. 321(2):2001;156-158.
14. Selim K., Kaplowitz N. Hepatotoxicity of psychotropic drugs. Hepatology. 29(5):1999;1347-1351.
15. Thompson J., Chengappa K.N., Good C.B., Baker R.W., Kiewe R.P., Bezner J., Schooler N.R. Hepatitis, hyperglycemia, pleural effusion, oesinophilia, hematuria and proteinuria occurring early in clozapine treatment. Int. Clin. Psychopharmacol. 13(2):1998;95-98.
16. Werapongset W., Chaisirikul S., Chrujiporn W., Visanuyothin T., Kessawai D., Charisilp C., Ratanachata N., Sanichwannakul K., Wangdee P., Bunditchate A., Ukranand P. Efficacy and tolerability of risperidone in chronic schizophrenic Thai patients. J. Med. Assoc. Thail. 81(5):1998;324-328.
17. Whitworth A.B., Liensberger D., Fleischhacker W.W. Transient increase of liver enzymes induced by risperidone: two case reports. J. Clin. Psychopharmacol. 19(5):1999;475-476.
18. Wirshing W.C., Ames D., Bisheff S., Pierre J.M., Mendoza A., Sun A. Hepatic encephalopathy associated with combined clozapine and divalproex sodium treatment. J. Clin. Psychopharmacol. 17(2):1997;120-121.